NICE Backs a Weight-Loss Injection to Help Prevent Heart Attacks and Strokes

Sep 30

3 min read

Updated: Oct 10

For a while now, weight-loss injections have mostly been talked about for one thing: helping people lose weight. But in 2026, NICE (the body that decides what treatments the NHS can offer) said something that surprised a lot of doctors. It recommended a weight-loss jab for a completely different reason — to help stop heart attacks and strokes happening again in people who've already had one.

This matters for a lot of people. Around 100,000 heart attacks and 100,000 strokes happen in the UK every year, and about 350,000 people live with peripheral arterial disease (poor blood flow, usually in the legs, caused by narrowed arteries). NICE says roughly 1.2 million people across the UK could benefit from this new use.

What NICE actually recommended

NICE's guidance says people who have already had a heart attack, a stroke, or who have peripheral arterial disease, and who have a BMI of 27 or higher, should be able to get semaglutide (the drug sold as Wegovy) on the NHS — alongside their usual heart medicines like statins, and alongside diet and exercise changes. This is a big deal because it's not really about losing weight this time. It's about protecting the heart and blood vessels directly.

Final NICE guidance is expected in May 2026. Once it's confirmed, the NHS in England has 90 days to make it available, and Wales has 60 days.

The trial behind the decision

The recommendation is based on a big study called SELECT, which followed thousands of adults with heart disease and a BMI of 27 or more (but without diabetes) for several years. People taking semaglutide were about 20% less likely to have another heart attack, stroke, or cardiovascular death compared with those on a dummy injection (placebo).

Here's the surprising part: the benefit started showing up quite quickly, before people had lost much weight at all. That's a strong clue that the drug isn't just protecting the heart by shrinking waistlines — something else seems to be going on too.

So what's actually happening in the body?

Scientists have tried to work out exactly why semaglutide protects the heart so well, and the honest answer in 2026 is: nobody fully knows yet. A detailed analysis of the SELECT trial found that things doctors normally measure — weight loss, blood pressure, cholesterol and blood sugar — only explain about 31% of the heart benefit. That leaves roughly two-thirds unexplained.

One clue is inflammation. A marker called CRP (C-reactive protein), which rises when there's inflammation in the body, dropped a lot in people taking the drug, and this seemed to account for a good chunk of the benefit. Researchers think the drug might also be acting directly on blood vessels, on fatty liver disease, or on fat around the heart itself — but they're clear these ideas are still speculative, not proven.

Why this isn't a simple "good news" story

Independent experts who reviewed NICE's decision welcomed it, but flagged some real caveats:

Cost. One expert pointed out that while the treatment is good value for each person who takes it, it won't save the NHS money overall, and paying for it for over a million people could be genuinely difficult to afford.
Trial data gaps. Most people in the SELECT trial were White, so it's less clear how well the drug works, and who might be missed by the BMI 27 cut-off, across different ethnic groups who can face higher heart risk at lower BMIs.
Muscle loss still matters here too. As with any GLP-1 medicine, some of the weight lost is muscle, not just fat. Doctors involved in reviewing the guidance specifically said resistance training should go alongside treatment to help protect strength, not just heart health.

The bottom line

This is a genuinely exciting update in heart health research, and it shows these medicines can do more than help people lose weight. But it's also a reminder that these are serious prescription-only medicines, being offered here for a specific medical reason, under specialist NHS criteria, alongside statins, diet, and exercise support — not a general-purpose treatment people should seek out on their own. Anyone interested needs a full assessment from a qualified clinician, who can look at their heart history, BMI, and overall health before deciding if it's right for them.